The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
The group is expanding its mRNA-4359 trial to include first-line melanoma.
FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
